SKYE BIOSCIENCE INC

Skye Bioscience’s weak 0.62% rise underscores shallow liquidity and low valuation, warning OTC biotech investors to scrutinize rather than chase hope.

Skye Bioscience (SKYE) jumps 5.9% as its price edges close to a 42‑fold discount from its 52‑week high, sparking interest from value‑oriented investors.